profit from every $100 of sales.
$0$100
Pfizer
$28.89+0.21% today
+12.0% in 1 year
1-year low $23.671-year high $30.79
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $21.19 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Pfizer sold, what it kept, and what it did with the cash.
Sales went from $101 billion in 2022 to $62.6 billion in 2025, with $7.77 billion of profit last year.
SalesProfit
Pfizer handed back more cash to shareholders than it generated last year.
$9.8B
Free cash flow 2025$9.1B
Bought back its own shares–
Paid as dividends$9.8B
Cash vs. debt$1.1B vs. $64.0B
Pfizer vs. similar companies
Pfizer grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Pfizer | 21.2× · Fair price | ||
 Eli Lilly | 62.3× · Very expensive | ||
 Johnson & Johnson | 25.7× · Fair price | ||
 AbbVie | 123.4× · Very expensive | ||
 Roche | 25.5× · Fair price |
Compare Pfizer with AbbVie · Johnson & Johnson · Eli Lilly · Merck & · Roche · UnitedHealth
AI analysis
An AI analyst reads Pfizer's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 41,651 | 81,288 | 101,175 | 59,554 | 63,627 | 62,579 | |
| 33,167 | 50,467 | 66,831 | 34,600 | 45,776 | 46,512 | |
| – | – | 37,164 | 4,223 | 14,830 | 15,794 | |
| 13,166 | 30,793 | 41,031 | 9,557 | 18,127 | 16,783 | |
| 9,159 | 21,979 | 31,372 | 2,119 | 8,031 | 7,771 | |
| 1.63 | 3.85 | 5.47 | 0.37 | 1.41 | 1.36 | |
| 79.6% | 62.1% | 66.1% | 58.1% | 71.9% | 74.3% | |
| – | – | 36.7% | 7.1% | 23.3% | 25.2% | |
| 22.0% | 27.0% | 31.0% | 3.6% | 12.6% | 12.4% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 154,229 | 181,476 | 197,205 | 226,501 | 213,396 | 208,160 |
| Cash | 1,786 | 1,944 | 416 | 2,853 | 1,043 | 1,142 |
| Total debt | 39,691 | 37,831 | 34,859 | 70,845 | 63,649 | 63,961 |
| Total liabilities | 90,756 | 104,013 | 101,289 | 137,213 | 124,899 | 121,385 |
| 63,238 | 77,201 | 95,661 | 89,014 | 88,203 | 86,476 | |
| 5,632 | 5,708 | 5,733 | 5,709 | 5,700 | 5,713 | |
| 6.5% | 17.6% | 21.8% | 1.6% | 5.8% | 5.4% | |
| 14.5% | 28.5% | 32.8% | 2.4% | 9.1% | 9.0% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 14,403 | 32,580 | 29,267 | 8,700 | 12,744 | 11,704 | |
| 2,226 | 2,711 | 3,236 | 3,907 | 2,909 | 2,629 | |
| 12,177 | 29,869 | 26,031 | 4,793 | 9,835 | 9,075 | |
| Dividends paid | – | – | 8,983 | 9,247 | 9,512 | 9,771 |
| 0 | 0 | 2,000 | 0 | 0 | – | |
| 755 | 1,182 | 872 | 525 | 877 | 799 |
Valuation
- 21.2×
- 9.8×
- –
- 2.0×
- 2.6×
- 18.1×
- 13.6×
- 5.5%
- 4.7%
- 6.6%
Profitability
- 74.3%
- 25.2%
- 12.4%
- 26.8%
- 5.5%
- 8.8%
- 8.4%
- 3.6%
- 8.6%
- 19.6%
Growth
- +8.5%
- −3.6%
- −7.7%
- +2.5%
- −0.1%
Financial health
- 3.7×
- 0.74
- 31.0%
- 3.8×
- 1.16
- 0.94
- 0.30
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 50%of 952
Top 13%of 883
Top 39%of 601
Bottom 44%of 888
Top 20%of 987
What analysts expect
- Average price target
- $27.40
- Range
- $24.00 – $35.00
- 5 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | 0.75 | 0.72 | +3.9% |
| Feb 3, 2026 | 0.66 | 0.57 | +16.4% |
| Nov 4, 2025 | 0.87 | 0.63 | +37.4% |
| Aug 5, 2025 | 0.78 | 0.58 | +34.5% |
| Apr 29, 2025 | 0.92 | 0.67 | +38.1% |
| Feb 4, 2025 | 0.63 | 0.47 | +33.6% |
| Oct 29, 2024 | 1.06 | 0.61 | +72.6% |
| Jul 30, 2024 | 0.60 | 0.46 | +31.0% |
6.6%of the share price, paid each year
On $1,000 invested$66a year at today's yield, before tax
+2.5%2020 to 2025
Raised10 yearsin a row, in our data
Paid per share, each year
$1.12 in 2015 → $1.72 in 2025
How safe it looks
125.7% of its profit
Room to growStretchedMore than it earns: 107.7%
News
Blackstone to provide Pfizer up to $1.5B to advance monthly GLP-1 for weight lossSeeking Alpha · Nov 11, 2026Pfizer Hits a New 52-Week High. Here's Why It's Not Too Late to Buy the StockYahoo Finance · Nov 10, 2026Notable healthcare headlines for the week: Moderna, Pfizer, and CVS Health in focusSeeking Alpha · Nov 8, 2026Pfizer raises 2026 outlook to $62B-$64B revenue and $2.95-$3.05 adjusted EPS, targeting high single-digit revenue CAGR from 2028-2033Seeking Alpha · Nov 4, 2026Pfizer Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Nov 3, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
47No pass
Benjamin Graham
57No pass
Philip Fisher
55No pass
Peter Lynch
30No pass
Joel Greenblatt
19No pass
Charlie Munger
45No pass
Terry Smith
46No pass
Questions about Pfizer
Is Pfizer a good stock to buy?
A business with weak numbers at a fair price. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Pfizer AI analysis
What does Pfizer do?
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. It is in Drug Manufacturers - General, based in New York, NY, United States, with 75,000 employees.
Does Pfizer pay a dividend?
Yes. At today's price the dividend is 6.6% a year, about 126% of its yearly profit. In 2025 it paid out $9.77 billion in dividends.
Is Pfizer stock halal?
No. Pfizer does not pass our halal screen: its debt is 39% of its market value, at or above the 33% limit. How we check
How has Pfizer stock done over the past year?
Up 12.0% over the past twelve months, to $28.89. It traded between $23.67 and $30.79 and is 6.2% below its high.
Who are Pfizer's competitors?
The largest listed companies in the same industry are Eli Lilly, Johnson & Johnson, AbbVie and Roche. The peers table on this page compares their profit, growth and price with Pfizer's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.